Literature DB >> 32943889

Alteration of Clinical Chemistry Parameters Among Visceral Leishmaniasis Patients in Western Tigrai, Ethiopia, 2018/2019: A Comparative Cross-Sectional Study.

Brhane Tesfanchal1, Gebremedhin Gebremichail2, Getachew Belay1, Gebreslassie Gebremariam3, Gebreyohannes Teklehaimanot4, Hagos Haileslasie2, Getachew Kahsu1, Aderajew Gebrewahd5, Fitsum Mardu6, Gebre Adhanom5, Brhane Berhe6, Hirut Teame7, Aster Tsegaye8, Mistire Wolde9.   

Abstract

BACKGROUND: Visceral leishmaniasis causes alterations of lipid metabolism and it is associated with hypocholesterolemia and severe hypertriglyceridemia. Hepatic dysfunction and life-threatening hepatitis are associated with visceral leishmaniasis. Kidney damage is frequently associated with increased morbidity and mortality in visceral leishmaniasis patients.
METHODS: A cross-sectional study was carried out to assess the alterations of clinical chemistry parameters among visceral leishmaniasis patients attending Kahsay Abera and Mearg hospitals, Northwest Ethiopia. A total of 100 visceral leishmaniasis patients and 100 healthy controls without visceral leishmaniasis were selected by using convenient sampling techniques. Data were entered and analyzed using statistical package for social sciences (SPSS) version 23.
RESULTS: Results were showed that the mean value of serum aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, and triglyceride was significantly higher in visceral leishmaniasis patients than in apparently healthy controls, but the mean value of serum urea and total cholesterol was significantly lower in visceral leishmaniasis patients than healthy controls.
CONCLUSION: The finding of this study concluded that visceral leishmaniasis causes significant alterations of clinical chemistry tests like liver and lipid profile tests compared to healthy controls.
© 2020 Tesfanchal et al.

Entities:  

Keywords:  kidney function test; lipid profile test; liver function test; visceral leishmaniasis

Year:  2020        PMID: 32943889      PMCID: PMC7467734          DOI: 10.2147/IDR.S261698

Source DB:  PubMed          Journal:  Infect Drug Resist        ISSN: 1178-6973            Impact factor:   4.003


  22 in total

1.  Hematologic changes in visceral leishmaniasis/kala azar.

Authors:  Neelam Varma; Shano Naseem
Journal:  Indian J Hematol Blood Transfus       Date:  2010-09-30       Impact factor: 0.900

2.  Visceral leishmaniasis masquerading as chronic liver disease.

Authors:  A Prakash; N P Singh; G Sridhara; V Malhotra; A Makhija; D Garg; Anjali Pathania; S K Agarwal
Journal:  J Assoc Physicians India       Date:  2006-11

3.  Plasma lipoproteins in visceral leishmaniasis and their effect on Leishmania-infected macrophages.

Authors:  N M Soares; T F Leal; M C Fiúza; E A G Reis; M A L Souza; W L Dos-Santos; L Pontes-de-Carvalho
Journal:  Parasite Immunol       Date:  2010-04       Impact factor: 2.280

4.  A review of leishmaniasis in west Africa.

Authors:  D A Boakye; Md Wilson; M Kweku
Journal:  Ghana Med J       Date:  2005-09

5.  Evaluation of renal function in human visceral leishmaniasis (kala-azar): a prospective study on 50 patients from Brazil.

Authors:  Francisco A A Lima Verde; Frederico A Lima Verde; Islene A Lima Verde; Geraldo B Silva Junior; Elizabeth F Daher; Emir M Lima Verde
Journal:  J Nephrol       Date:  2007 Jul-Aug       Impact factor: 3.902

6.  Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis.

Authors:  Mansour Nassiri Kashani; Alireza Firooz; Seyed Ebrahim Eskandari; Mohammad Hossein Ghoorchi; Ali Khamesipour; Alireza Khatami; Amir Javadi; Yahya Dowlati
Journal:  Eur J Dermatol       Date:  2007-10-19       Impact factor: 3.328

7.  High prevalence of functional liver derangement in visceral leishmaniasis at an Indian tertiary care center.

Authors:  Purva Mathur; Jyotish Chandra Samantaray; Palash Samanta
Journal:  Clin Gastroenterol Hepatol       Date:  2008-07-10       Impact factor: 11.382

8.  Biochemical and nutritional evaluation of patients with visceral leishmaniasis before and after treatment with leishmanicidal drugs.

Authors:  Mariana Gatto; Mariana Miziara de Abreu; Karen Ingrid Tasca; José Cláudio Simão; Carlos Magno Castelo Branco Fortaleza; Paulo Câmara Marques Pereira; Sueli Aparecida Calvi
Journal:  Rev Soc Bras Med Trop       Date:  2013 Nov-Dec       Impact factor: 1.581

9.  The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14.

Authors:  Priscila L Dos Santos; Fabrícia A de Oliveira; Micheli Luize B Santos; Luana Celina S Cunha; Michelle T B Lino; Michelle F S de Oliveira; Manuela O M Bomfim; Angela Maria Silva; Tatiana R de Moura; Amélia R de Jesus; Malcolm S Duthie; Steven G Reed; Roque P de Almeida
Journal:  PLoS Negl Trop Dis       Date:  2016-01-27

10.  Liver morphology and function in visceral leishmaniasis (Kala-azar).

Authors:  I A el Hag; F A Hashim; I A el Toum; M Homeida; M el Kalifa; A M el Hassan
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.